Workshop on the Prevention of Group A Streptococcal Diseases and their Sequelae with a Focus on Vaccine-Related Issues
March 29-30, 2004
Fernwood Building
Bethesda, MD
Goal
To develop a strategy for further clinical development of group A streptococcal vaccines and their implementation.
Agenda
Downloadable version (PDF)
| Time |
Topic |
Speaker |
| March 29th, 2004 |
|
|
| 8:30-8:45 |
Welcome and introductions Goal of the workshop |
Fran Rubin |
| 8:45-9:10 |
Overview Including historical view of vaccine development |
Alan Bisno |
| 9:10-10:10 |
Epidemiology/ Burden of Disease |
Jonathan Carapetis
Anne Schuchat |
| 10:10-10:30 |
Break |
|
| 10:30-12:00 |
Immunology/pathogenesis considerations for vaccine development including animal models |
Madeleine Cunningham
Malak Kotb |
| 12:00-1:00 |
Lunch |
|
| 1:00-2:00 |
Immune correlates including laboratory considerations (serological assays) |
Pat Cleary
Jim Dale |
| 2:00-3:20 |
Vaccine clinical trial design |
Karen Kotloff
Kate O’ Brien |
| 3:20-3:40 |
Break |
|
| 3:40-4:20 |
Perspective from industry |
4 presentations |
| 4:20-5:30 |
FDA considerations for vaccine development |
Marion Gruber
Chris Mink
Norman Baylor |
| Time |
Topic |
Speaker |
| March 30th, 2004 |
|
|
| 8:00-9:45 |
Implementation: US, Global, Economics |
Jeff Davis
Thomas Cherian
Amie Batson |
| 9:45-10:00 |
Break |
|
| 10:00-10:30 |
Identification of obstacles for vaccine development and gaps in knowledge |
Sam Katz |
| 10:45-12:30 |
Break out sessions |
|
| 12:30-1:30 |
Lunch |
|
| 1:30-2:50 |
Recommendations/Discussion
Breakout groups |
Sam Katz
Stan Shulman |
| 2:50-3:20 |
Next steps moving forward |
Orin Levine |
| 3:20-3:35 |
Break |
|
| 3:35-3:45 |
Summary |
Alan Bisno |
List of Participants
Downloadable version (PDF)
back to top